PUSHUP: PK-guided vs Weight-based Hydroxyurea in African Children with Sickle Cell Anemia

Phase 3, randomised, open-label trial of hydroxyurea in sickle cell anemia (SCA) (2 arms), sponsored by Brown University. Primary endpoints: Rate of clinical, sickle cell adverse events (grade >= 3) at 12 months and Number of non-SCA related adverse events (grade >=3), including death at 24 months. Started Nov 2023; status: recruiting.